
æ¥æ§äžç çã«å¯Ÿããã«ã³ããããŒã«ïŒRCTã§å ¥ç åŸã®èŠéã«æ¹åãªã
ã«ã³ããããŒã«ïŒCBNïŒã¯ãèªç¶ãªç¡ç è£å©è¬ãšããŠè²©å£²ãããŠãã軜床ã®ç²Ÿç¥æŽ»æ§ã«ã³ãããã€ãã§ãããã峿 Œãªã©ã³ãã 忝èŒè©Šéšã«ãããŠãå ¥ç åŸã®èŠéïŒWASOïŒãææã«æžå°ãããªãã£ãããããããã¹ããããé«çšéã¯ç¡ç ã®è³ªã«é¢ããããã€ãã®å¯æ¬¡è©äŸ¡é ç®ãæ¹åããã ãªãŒã CBNã¯ãéåŠæ¹ã®ç¡ç ãµããªã¡ã³ããšããŠäººæ°ãåããŠããããªã€ã«ãã°ããã«ãã»ã«ãªã©ã§è²©å£²ãããå埩çãªç¡ç ãä¿é²ãããšè¬³ãããŠãããæ¶è²»è ã®éã§åºã䜿çšãããŠããã«ããããããã峿 Œãªèšåºçãšããã³ã¹ã¯äžè¶³ããŠããããŠãŒã«ã³ãã¯å»åŠç ç©¶æããã³ã·ãããŒå€§åŠã®ç ç©¶è ãã«ããæ°ããªã©ã³ãã åäºéç²æ€ãã©ã»ãå¯Ÿç §ã¯ãã¹ãªãŒããŒè©Šéšã¯ãäžç çãšèšºæããã人ã ã察象ã«ãCBNã®å®¢èгçã«æž¬å®ãããç¡ç ãžã®åœ±é¿ã«ã€ããŠããããŸã§ã§æã管çããã詊éšãæäŸããã çµæ å»åž«ããäžç çé害ãšèšºæãããäžç çéçåºŠææ°ã15以äžã®æäºº20åïŒå¥³æ§17åãç·æ§3åãå¹³å幎霢42æ³ïŒãã30 mgã®CBNã300 mgã®CBNããŸãã¯å¯Ÿå¿ãããã©ã»ãã®3ã€ã®äžæ©ä»å ¥ãã©ã³ãã ãªé åºã§åãã2é±éã®ãŠã©ãã·ã¥ã¢ãŠãæéã§åºåããããçµå€ããªãœã ãã°ã©ãã£ãŒã«ãããäž»èŠè©äŸ¡é ç®ãšããŠWASOãæž¬å®ãããã ãããã®çšéãWASOã®çµ±èšçã«ææãªæžå°ããããããªãã£ãã300 mgæäžã§ã¯å¹³å6,3åã®æžå°ïŒ95 % CIïŒâ18,2ã+5,5ãp = 0,29ïŒã30 mgæäžã§ã¯4,0åã®æžå°ïŒ95 % CIïŒâ15,9ã+7,9ãp = 0,50ïŒã§ãã£ããä¿¡é Œåºéã¯åºããŒãããŸããã§ããããã®äž»èŠè©äŸ¡é ç®ã«çã®å¹æããªãããšãšäžèŽããŠããã ãããã300 mgæäžã§ã¯ãããã€ãã®å¯æ¬¡çãªç¡ç ææšã«æ¹åãèŠããããNREMã¹ããŒãž2ç¡ç æéã®ææãªå¢å ïŒp = 0,03ãCohen’s dz = 0,54ïŒãå ¥ç æœæã®ççž®ïŒp = 0,004ãdz = â0,74ïŒãEEGèŠéææ°ã®äœäžïŒp = 0,02ãdz = â0,65ïŒãããã³äž»èгçãªç¡ç ã®è³ªã®è©äŸ¡ã®æ¹åïŒp = 0,005ãdz = 0,56ïŒãèªããããã30 mgæäžã§ã¯ããããã®å¯æ¬¡è©äŸ¡é ç®ã«ãææãªå¹æã¯èŠãããªãã£ãã ãã®ç ç©¶ã¯ClinicalTrials.govã«èå¥åNCT05344170ãšããŠç»é²ããã2022幎8æãã2023幎9æãŸã§åå è ãåéããã ãã©ã»ããå«ãå šè©ŠéšçŸ€ã§åèš247ä»¶ã®è»œåºŠããäžçåºŠã®æå®³äºè±¡ãèšé²ãããéç¯€ãªæå®³äºè±¡ã¯å ±åãããªãã£ããæãäžè¬çã«å ±åããã广ã¯é®éãããŸããèè žäžå¿«æã§ãã£ããããããã¯æ²»ç矀ãšãã©ã»ã矀ã§åçšåºŠã®çºççã§ãã£ãã éèŠæ§ ãã®è©Šéšã¯éèŠãªã®ã£ããã«å¯ŸåŠãããã®ã§ãããCBNã¯åžè²©ã®ç¡ç 補åã«åºã䜿çšãããŠãããããããŸã§äžç çéå£ã察象ã«ã客芳çãªç¡ç 枬å®ã䌎ã管çãããå®éšå®€ç°å¢ã§ãã©ã»ããšæ¯èŒè©Šéšãããããšã¯ãªãã£ããäž»èŠè©äŸ¡é ç®ã®é°æ§çµæã¯éèŠã§ãããWASOã®6åã®æ¹åã¯èšåºçã«ç¡èŠã§ãããã®ã§ãããä¿¡é Œåºéã¯ç¡ç ç¶æãšããäžç çã®äžæ žçç¶ã«å¯ŸããææçŸ©ãªå©çãæé€ããŠãããå ¥ç ãšç¡ç 深床ã«é¢ãã坿¬¡çãªã·ã°ãã«ã¯ãããªã調æ»ã«å€ããããCBNã广çãªäžç çæ²»çãšããŠç¢ºç«ãããã®ã§ã¯ãªãã éç ãµã³ãã«ã¯å°èŠæš¡ïŒn = 20ïŒã§ã女æ§ã倧åãå ããŠãããäžæ©ã®ã¿ã®ãã¶ã€ã³ã¯æ¥æ§å¹æã®ã¿ãæããèæ§ãé¢è±ããŸãã¯æç¶çãªæå¹æ§ãè©äŸ¡ããããšã¯ã§ããªãã2é±éã®ãŠã©ãã·ã¥ã¢ãŠãæéãèšããã¯ãã¹ãªãŒããŒãã¶ã€ã³ã¯ãåæžæã®é·ãã«ã³ãããã€ãã«ã¯äžååã§ããå¯èœæ§ããããå šçŸ€ã§ã®è»œåºŠããäžçåºŠã®æå®³äºè±¡ã®çºççã®é«ãã¯æ³šç®ã«å€ãã䞻芳ççµæã®è§£éãè€éã«ããŠããã çµè« CBN 30 mgãŸãã¯300 mgã¯ãäžç çéå®³ã®æäººã«ãããå ¥ç åŸã®èŠéãæ¹åããªãã£ããé«çšéã¯å ¥ç æœæã䞻芳çãªç¡ç ã®è³ªãªã©ã®ããã€ãã®å¯æ¬¡ãã©ã¡ãŒã¿ãæ¹åãããããããã®ç¥èŠã¯äºåçãªãã®ã§ãããèšåºçæšå¥šãè¡ãããåã«ãããå€§èŠæš¡ã§é·æçãªè©Šéšã§ã®åçŸãå¿ èŠã§ããã åºå ž Lavender IG, Marshall [âŠ]










